Interview with Igor Varlamov, CEO, Binnopharm
Binnopharm was established in 2006, with 100% of charter capital coming from holding company JSFC Sistema. What was the vision behind the creation of Binnopharm? The company was indeed established…
Address: 124460, г. Москва, г. Зеленоград, 4-й Западный проезд, дом 3, строение 1,Russia
Tel: +7 (495) 510-3288
Closed Joint-Stock Company “Binnopharm” (Moscow, Zelenograd) is formed with a 100% charter capital belonging to JFC Sistema with investment volume more than 4.3 bln RUR (50% in CAPEX).
CJSC “Binnopharm” is CJSC “Binnopharm” with its productive area more than 32 thous м2 is one of the most large-scaled biopharmaceutical companies in Russia. Biotechnological and pharmaceutical complex “Binnopharm” has the largest in Russia biotech medicines manufacture with complete production cycle. Production is built according to GMP (Good Manufacturing Practice) quality standards. Company also has a unique biotech Research & Development center. “Binnopharm” complex is fully equipped with multipurpose production lines provided by top international players for the full-cycle production of biotech medicines like: tablets, capsules, ampoules, sprays and environment friendly aerosols.
Top-priority course for the company’s activities is focused on developing and commercial availability of medicines across socially significant diseases such as oncology, hematology, infections and respiratory ones, genetically engineered medicines, vaccines and fibroblast-tissue technologies’ products in regenerative medicine.
CJSC “Binnopharm” is the founder and the basis of the Moscow nanobiopharmaceutical cluster “Biocity” that is located on the territory of Moscow Special Economic Zone “Zelenograd” – industrial technology park specialized in developing and implementation of innovating medicines as well as allocation of the best western elaborations and technologies on the territory of Russia.
Activity of «Binnopharm» Company aims at production of innovative medical aids that meet GMP international standards and implementation of an import replacement program. Here are set production lines for releasing of basic dosage forms: pills, capsules, vials and ecologically safe aerosols. «Binnopharm» is also a distributor of pharmaceutical substances and off-the-shelf dosage forms.
Biotechnology and genetic engineering have special status in the activity of «Binnopharm» Company. The enterprise possesses a unique full-cycle biotechnological production in Russia, with the most integrated and equipped laboratory for biotechnological preparation quality control. Here is produced a vaccine against the viral Hepatitis B – Regevac B.
Vaccine «Regevac B» produced now by «Binnopharm» CJSC, as to its properties, meets the World Health Organization’s requirements, and it is not inferior to, and upon certain indicators – leaves behind the foreign analogs. It is the most efficient and expedient recombinant vaccine for use in the territory of the Russia, produced on the basis of Hepatitis B virus’ strain, serotype ay.
Basic therapeutic groups of preparations, the production of which is projected in the new «Binnopharm» complex, are: haematology, oncology, infectious diseases, and respiratory diseases. Underway is development of biotechnological preparations that have principally new therapeutic opportunities, including treatment of diseases incurable in the past (cancer, AIDS, disseminated sclerosis), as well as new transport nanoforms. The Company’s production line has been continuously expanding.
Binnopharm was established in 2006, with 100% of charter capital coming from holding company JSFC Sistema. What was the vision behind the creation of Binnopharm? The company was indeed established…
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in…
The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of…
GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s…
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Pepeliaev, Goltsblat & Partners and the major UK firm Berwin Leighton Paisner (BLP). It calls itself the first international Russian law firm. Can you explain to our readers the rationale…
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
You were working for GSK since 2003 before joining Galderma this year. Some within the industry might view Galderma as a step down from the third-ranked pharmaceutical company in the…
Janssen recently signed memorandums of understanding with both the Skolkovo Foundation and ChemRar. Can you describe the strategic parameters and intended outcomes of these agreements? How do they factor into…
Mr. Demidov, you are one of the pioneers of market research studies in Russia. There is a quote you like to use: ‘Market research is a business in the United…
How would you describe CMS’s own presence in the life sciences field in Russia, and what unique competitive advantages does the firm bring to this area of practice? Over the…
With the announcement of the Pharma 2020 strategy to develop the domestic pharmaceutical industry, multinational companies have pledged an excess of $1Bn in investment into local infrastructure. Servier, however, preempted…
See our Cookie Privacy Policy Here